Intervention Review

Molindone for schizophrenia and severe mental illness

  1. Anne-Marie Bagnall1,*,
  2. Mark Fenton2,
  3. Jos Kleijnen3,
  4. Ruth Lewis4

Editorial Group: Cochrane Schizophrenia Group

Published Online: 24 JAN 2007

Assessed as up-to-date: 13 NOV 2006

DOI: 10.1002/14651858.CD002083.pub2


How to Cite

Bagnall AM, Fenton M, Kleijnen J, Lewis R. Molindone for schizophrenia and severe mental illness. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD002083. DOI: 10.1002/14651858.CD002083.pub2.

Author Information

  1. 1

    Leeds Metropolitan University, Faculty of Health, Leeds, UK

  2. 2

    James Lind Initiative, Database of Uncertainties about the Effects of Treatments (DUETs), Oxford, UK

  3. 3

    Kleijnen Systematic Reviews Ltd, York, UK

  4. 4

    Cardiff University, Department of General Practice, Wrexham, UK

*Anne-Marie Bagnall, Faculty of Health, Leeds Metropolitan University, Calverley Street, Leeds, LS1 3HE, UK. A.Bagnall@leedsmet.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 24 JAN 2007

SEARCH

  1. Current Version

    Molindone for schizophrenia and severe mental illness

    Anne-Marie Bagnall, Mark Fenton, Jos Kleijnen and Ruth Lewis

    Version of Record online: 24 JAN 2007 | DOI: 10.1002/14651858.CD002083.pub2

Previous versions of this article and their online publication dates

  1. Version 1

    Molindone for schizophrenia and severe mental illness

    A-M Bagnall, M Fenton, R Lewis, ML Leitner and J Kleijnen

    Version of Record online: 24 APR 2000 | DOI: 10.1002/14651858.CD002083